A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer

作者：Qiuji Wu, Qiu Li, Yi Qin · 发表于：Lung Cancer · 年份：2025 · DOI：10.1016/j.lungcan.2025.108533 · 被引用次数：8 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment、Health Systems, Economic Evaluations, Quality of Life